5-Amino-1MQ Quick Start
5-Amino-1MQ is short for 5-amino-1-methylquinolinium. It is a small molecule, not a true peptide, even though it is often sold alongside research peptides. Researchers study it for two main goals: helping the body shrink fat cells and raising NAD+ levels inside cells without cutting appetite.
It works by blocking an enzyme called NNMT (nicotinamide N-methyltransferase). When NNMT runs too high in fat tissue, it wastes a form of vitamin B3 that the body needs to make NAD+. NAD+ is the cellular energy currency. Block NNMT, save the B3, raise NAD+, and fat cells start working more like lean tissue. That, in plain English, is the whole story.
Most research-context use is oral capsules at 50 to 150 mg per day. A subcutaneous (under-the-skin) vial format exists, but the dose volume math makes injection awkward at common doses. This page covers both, with the oral route first.
Why researchers care
Fat-cell shrinkage and higher NAD+ without appetite suppression.
Class
Small-molecule NNMT inhibitor. Not a peptide.
Most common route
Oral capsule, 50 to 150 mg per day, taken in the morning.
Cycle length
8 to 12 weeks on, 4 to 6 weeks off in common research community protocols.
Status
Not FDA-approved as of May 2026. No published human trials.
Educational reference only
This page is a research-context summary, not personal medical advice. 5-Amino-1MQ is sold under research-use-only labeling and is not an FDA-approved treatment. Talk to a qualified clinician before any use.
5-Amino-1MQ Dosing Protocol & Schedule
5-Amino-1MQ has no human clinical trial to set a dose. The numbers below come from two places: rodent studies scaled to a human size (allometric scaling) and several years of research community use reports. Both routes are covered. Pick the tab that matches what you are planning around.
5-Amino-1MQ Protocol Formats
Choose the format you are researching to see route-specific notes.
Less common. Used when the research compound is sold as a lyophilized vial.
Some research suppliers sell 5-Amino-1MQ as a lyophilized (freeze-dried) 50 mg vial. The subcutaneous route is used at much smaller doses than oral because a 100 mg injection would require two 50 mg vials and about 6 mL of liquid when each vial is mixed with 3.0 mL BAC water, which is too much for one subcutaneous site.
Subcutaneous planning from a 50 mg vial reconstituted with 3.0 mL BAC water (~16.7 mg/mL)
Phase
Days 1–2 (tolerance)
Daily dose
2.5 mg once daily
Units on U-100 syringe
15 units
Volume
0.15 mL
Phase
Days 3+ (standard)
Daily dose
5 mg once daily
Units on U-100 syringe
30 units
Volume
0.30 mL
Phase
Split option (BID)
Daily dose
2.5 mg twice daily
Units on U-100 syringe
15 units each
Volume
0.15 mL each
| Phase | Daily dose | Units on U-100 syringe | Volume |
|---|---|---|---|
| Days 1–2 (tolerance) | 2.5 mg once daily | 15 units | 0.15 mL |
| Days 3+ (standard) | 5 mg once daily | 30 units | 0.30 mL |
| Split option (BID) | 2.5 mg twice daily | 15 units each | 0.15 mL each |
Subcutaneous doses are much smaller than oral doses because of injection volume limits and because direct subQ absorption skips the gut. This is not a dosing recommendation.
A single 50 mg vial lasts roughly 10 to 20 days at these subcutaneous doses. Rotate injection sites (abdomen, outer thigh, back of upper arm) to lower the chance of local irritation. A mild stinging sensation is common with this compound because of its quinolinium chemistry.
The standard route in research community use and in most published guides.
Oral capsules are the standard format for 5-Amino-1MQ. Capsules are usually sold in 50 mg units. The Neelakantan 2018 paper showed strong oral absorption in cell uptake (Caco-2) assays, which is why most research community use is by mouth instead of by injection.
Oral dosing ranges discussed in research community use
Phase
Weeks 1–2 (start low)
Daily dose
50 mg once daily
Notes
Take in the morning. Watch for any sleep, energy, or digestion changes.
Phase
Weeks 3+ (standard)
Daily dose
100 mg once daily
Notes
The most common research community target dose.
Phase
Weeks 3+ (higher end)
Daily dose
150 mg once daily
Notes
Some sources go this high. Diminishing returns and more side effects are reported above 150 mg.
Phase
Split option
Daily dose
50 mg morning + 50 mg midday
Notes
Some sources prefer split AM dosing because the plasma half-life is short (about 4 to 7 hours in rodent PK).
| Phase | Daily dose | Notes |
|---|---|---|
| Weeks 1–2 (start low) | 50 mg once daily | Take in the morning. Watch for any sleep, energy, or digestion changes. |
| Weeks 3+ (standard) | 100 mg once daily | The most common research community target dose. |
| Weeks 3+ (higher end) | 150 mg once daily | Some sources go this high. Diminishing returns and more side effects are reported above 150 mg. |
| Split option | 50 mg morning + 50 mg midday | Some sources prefer split AM dosing because the plasma half-life is short (about 4 to 7 hours in rodent PK). |
Reflects research community structure scaled from rodent data. This is not a dosing recommendation.
Cycle structure: the common research community cycle is 8 to 12 weeks on, then 4 to 6 weeks off. The off-period gives the body a chance to reset baseline NNMT activity. Take 5-Amino-1MQ in the morning only. Evening dosing has been linked to sleep disruption because of the metabolic activation effect.
No human trial dose exists
Every dose number above comes from rodent studies scaled to a human size or from research community use. No human clinical trial of 5-Amino-1MQ has been published. Treat these numbers as research-context structure only.
5-Amino-1MQ Reconstitution Guide
Reconstitution only applies if you are using a lyophilized 50 mg vial. If you are using oral capsules, skip this section. The example math below uses 3.0 mL of bacteriostatic water per 50 mg vial, which gives roughly 16.7 mg/mL of compound in solution. Do not use more than 3.0 mL BAC water in this vial format.
Reconstitution math for the 50 mg 5-Amino-1MQ vial
BAC water added
1.0 mL
Concentration
50.0 mg/mL
1 unit (U-100) equals
0.50 mg (500 mcg)
BAC water added
2.0 mL
Concentration
25.0 mg/mL
1 unit (U-100) equals
0.25 mg (250 mcg)
BAC water added
3.0 mL
Concentration
16.7 mg/mL
1 unit (U-100) equals
0.167 mg (167 mcg)
| BAC water added | Concentration | 1 unit (U-100) equals |
|---|---|---|
| 1.0 mL | 50.0 mg/mL | 0.50 mg (500 mcg) |
| 2.0 mL | 25.0 mg/mL | 0.25 mg (250 mcg) |
| 3.0 mL | 16.7 mg/mL | 0.167 mg (167 mcg) |
Use 3.0 mL as the maximum BAC-water volume for this 50 mg vial format. Lower volumes are more concentrated and use fewer syringe units.
- 01
Bring the vial to room temperature
Take the vial out of the freezer and let it sit on the counter for 15 to 20 minutes. This prevents condensation when the seal opens.
- 02
Wipe the vial top
Use a fresh alcohol swab on the rubber stopper of both the 5-Amino-1MQ vial and the BAC water vial.
- 03
Draw BAC water
Use a clean syringe to draw 3.0 mL of bacteriostatic water from its vial.
- 04
Add slowly
Insert the needle and let the water run down the inside wall of the vial. Do not blast it directly onto the powder.
- 05
Swirl, do not shake
Gently swirl or roll the vial between your hands until the powder dissolves into a clear solution.
- 06
Inspect
The solution should be clear with no cloudy particles. If it looks off, do not use the vial.
- 07
Label and refrigerate
Write the reconstitution date on the vial. Store at 2 to 8 °C (35.6 to 46.4 °F). Use within 2 to 4 weeks.
- 08
Draw your dose
Use a fresh U-100 insulin syringe for each session. Match the unit mark to the table above for your chosen concentration.
Need custom vial math?
If your vial size, BAC water volume, or target dose is different, use the calculator for exact unit conversions.
How 5-Amino-1MQ Works
5-Amino-1MQ blocks one enzyme: NNMT (nicotinamide N-methyltransferase). That single block sets off a chain of changes inside fat cells.
Here is the plain-English version. Your body uses a form of vitamin B3 called nicotinamide to build NAD+, the energy currency that powers mitochondria and many cell-repair processes. NNMT is an enzyme that grabs nicotinamide and methylates it, turning it into a waste product called 1-MNA that gets cleared from the body. In obesity, NNMT activity is unusually high in fat cells, which means a lot of nicotinamide gets thrown out before it can be turned into NAD+.
5-Amino-1MQ stops that waste step. With NNMT blocked, nicotinamide stays in the cell, NAD+ levels climb, and fat cells start burning more fuel instead of storing it. Researchers also observed shifts in glucose uptake and sirtuin activity (the SIRT1 longevity protein family) when NNMT was blocked.
Blocks NNMT in fat cells
In 3T3-L1 mouse fat cells, 30 µM of 5-Amino-1MQ for 24 hours strongly lowered 1-MNA levels — direct proof of NNMT inhibition (Neelakantan et al., Biochemical Pharmacology, 2018).
Raises NAD+ and SAM
The same study showed that NAD+ and S-adenosyl-methionine (SAM) both went up after NNMT inhibition. LC-MS/MS measurements confirmed both cofactors rose.
Shrinks fat cells in mice
In diet-induced obese mice, 11 days of 5-Amino-1MQ (subcutaneous, around 34 mg/kg/day) reduced body weight, total fat mass, and plasma cholesterol with no drop in food intake or lean mass.
Confirmed at 28 days
A follow-up 28-day study (Babula et al., 2024) extended the finding: 5-Amino-1MQ dose-dependently limited body weight and fat mass gain without changing food intake, and it improved liver markers in obese mice.
5-Amino-1MQ Supplies Needed
The supplies math below covers the subcutaneous 50 mg vial route. If you are using oral capsules, you only need the capsules themselves — no syringes or BAC water.
Recommended Supply
Use discount code PEPPAL at eligible peptide supplier checkouts.
5-Amino-1MQ
SiPhox Health At-Home Blood Test
Injection Supplies
Disclosure: supply links may earn PDP a commission at no cost to you.
Vials (50 mg each, subcutaneous route only)
One 50 mg vial lasts about 10 to 20 days at 2.5 to 5 mg per day.
| Cycle length | Planning note |
|---|---|
2 weeks 1 vial | Covers about 10 to 20 days at the example doses. |
4 weeks 2 vials | Roughly one vial every two weeks. |
8 weeks 4 vials | Plan extra margin for priming losses. |
12 weeks 6 vials | Full standard cycle length. |
2 weeks
1 vial
Covers about 10 to 20 days at the example doses.
4 weeks
2 vials
Roughly one vial every two weeks.
8 weeks
4 vials
Plan extra margin for priming losses.
12 weeks
6 vials
Full standard cycle length.
Insulin Syringes (U-100)
One fresh syringe per injection. The example subQ doses fit a 0.5 mL barrel.
| Cycle length | Planning note |
|---|---|
2 weeks 14 syringes | 1 syringe per day at once-daily dosing. |
4 weeks 28 syringes | 1 syringe per day. |
8 weeks 56 syringes | 1 syringe per day. |
12 weeks 84 syringes | 1 syringe per day. Add more if running twice-daily. |
2 weeks
14 syringes
1 syringe per day at once-daily dosing.
4 weeks
28 syringes
1 syringe per day.
8 weeks
56 syringes
1 syringe per day.
12 weeks
84 syringes
1 syringe per day. Add more if running twice-daily.
Bacteriostatic Water
Use up to 3.0 mL per 50 mg vial. One 10 mL bottle covers three vials with margin.
| Cycle length | Planning note |
|---|---|
2-4 weeks 1 × 10 mL bottle | 2 weeks: Uses 3 mL of one bottle.; 4 weeks: Uses 6 mL of one bottle. |
8-12 weeks 2 × 10 mL bottles | 8 weeks: Uses 12 mL across the cycle.; 12 weeks: Uses 18 mL across the cycle. |
2-4 weeks
1 × 10 mL bottle
2 weeks: Uses 3 mL of one bottle.; 4 weeks: Uses 6 mL of one bottle.
8-12 weeks
2 × 10 mL bottles
8 weeks: Uses 12 mL across the cycle.; 12 weeks: Uses 18 mL across the cycle.
Numbers round up for priming losses and small protocol changes. If you are using oral capsules, none of the above applies — you only need the capsules themselves.
Who 5-Amino-1MQ Is For and Who Should Avoid It
5-Amino-1MQ has no FDA-approved use, so there is no formal eligibility list. The list below reflects how the published rodent studies were set up and what is known about NNMT in human biology.
- Pregnancy and breastfeeding: not studied. Avoid.
- Active cancer or recent cancer history: NNMT plays a complex role in cancer biology. In some tumor types, NNMT activity helps the tumor grow; in others, the picture is less clear. Until human safety data exists, anyone with a cancer history should avoid 5-Amino-1MQ outside formal oncology research.
- Liver disease: liver enzyme monitoring is recommended in community use, and a baseline ALT/AST check is reasonable before starting.
- Children and teenagers: no safety data exists.
- Anyone taking methyl-donor-sensitive medications (some psychiatric drugs, methotrexate, methylated B-vitamin protocols at high doses): NNMT shares the methyl donor SAM, so theoretical interactions exist.
- People with known sleep disorders: the metabolic activation effect can worsen insomnia if dosed late in the day.
If any of those apply, talk to a qualified clinician before considering 5-Amino-1MQ for any reason.
5-Amino-1MQ Side Effects & Safety
5-Amino-1MQ has no published human safety trial. The list below comes from rodent toxicity data and from research community use reports. Read it as what has been reported, not as what is known to be safe long-term.
Most commonly reported
- Mild stimulant-like effects (warmth, slight resting heart-rate rise) in the first 1 to 2 weeks.
- Insomnia if dosed in the afternoon or evening — the most preventable side effect on the list.
- Mild stomach upset with oral capsules in some users.
- Stinging at the injection site with the subcutaneous route, due to the quinolinium chemistry.
- Reduced exercise tolerance during the first weeks of cardiovascular training, per some research community reports.
Theoretical or under-studied
- Liver enzyme changes — community use guides recommend a baseline ALT/AST check and a recheck during long cycles.
- Cancer risk in people with a cancer history, because of NNMT's complex role in tumor biology.
- Long-term effects of repeated cycles have not been mapped in any published study.
- Drug interactions with methyl-donor-sensitive medications are theoretical, not confirmed.
Quality-control risks
Because 5-Amino-1MQ is sold under research-use-only labels, batch purity and identity depend on the supplier. Capsule products are not regulated as supplements, so dose accuracy varies. Match the certificate of analysis (COA) to the exact lot before any use. Treat poorly documented capsules as the bigger near-term risk, not the compound itself.
5-Amino-1MQ Timeline & What to Monitor
5-Amino-1MQ works through slow metabolic changes inside fat cells, not through appetite suppression. That means visible body composition changes take longer than with GLP-1 drugs.
- Weeks 1–2: most users notice subtle warmth and slightly higher resting heart rate. No body composition change yet.
- Weeks 4–6: first measurable waist or body-fat changes in responders, based on research community reports.
- Weeks 8–12: peak reported effect in community-use cycles. The Babula 2024 mouse study saw clear fat-mass reduction at 28 days, which scales roughly to 6–10 weeks in humans.
- Off-period (weeks 12+): 4 to 6 weeks off lets baseline NNMT activity reset before the next cycle.
Reasonable markers to track: waist circumference, weight, resting heart rate, sleep quality, and a basic liver panel (ALT, AST) before and after long cycles. There is no validated lab marker for NNMT inhibition outside research labs.
5-Amino-1MQ Clinical Evidence Context
All current 5-Amino-1MQ evidence is preclinical — cell culture and rodent studies. There is no published human clinical trial of 5-Amino-1MQ. The strongest data comes from Harshini Neelakantan, Stan Watowich, and colleagues at the University of Texas Medical Branch (UTMB).
Cell-culture (3T3-L1 adipocytes)
5-Amino-1MQ at 30 µM strongly reduced 1-MNA levels in mouse fat cells, confirming NNMT inhibition (Neelakantan et al., Biochemical Pharmacology, 2018).
Rodent (diet-induced obesity, 11 days)
Subcutaneous 5-Amino-1MQ at roughly 34 mg/kg/day reduced body weight and white adipose mass without changing food intake or lean mass.
Rodent (diet-induced obesity, 28 days)
Babula et al. (2024) confirmed dose-dependent body-weight and fat-mass reduction over a longer treatment window, with improvements in fatty-liver markers.
Rodent (lean diet combination)
Sampson et al. (Scientific Reports, 2021) reported that NNMT inhibition plus a lean-diet substitution lowered body weight, fat mass, and liver fat beyond either intervention alone.
Genetic proof-of-concept
Kraus et al. (Nature, 2014) used an antisense oligonucleotide to knock down NNMT in mice and reported reduced fat-mass gain, better glucose tolerance, and lower liver triglycerides — the founding paper for the whole NNMT-inhibitor field.
Key gap: no human trial has been published, and no human pharmacokinetic study is widely available. Dose ranges come from allometric scaling (using a math formula to translate a mouse mg/kg dose into a human dose) and from research community use. That is far weaker than a Phase 1 human trial.
5-Amino-1MQ Storage & Handling
Capsules and vials follow different storage rules.
5-Amino-1MQ storage by format
Form
Capsules (sealed container)
Temperature
Room temperature
Note
Keep in a cool, dry, dark place. Stable up to 12 months at room temperature.
Form
Lyophilized vial (long-term)
Temperature
-4 °F (-20 °C) or colder
Note
Best for long storage. Stable up to 24 months.
Form
Lyophilized vial (short-term)
Temperature
35.6 to 46.4 °F (2 to 8 °C)
Note
Acceptable for short transit and short holds.
Form
Reconstituted vial
Temperature
35.6 to 46.4 °F (2 to 8 °C)
Note
Refrigerate. Use within 2 to 4 weeks. Do not refreeze.
Form
Appearance
Temperature
Clear after mixing
Note
Cloudy or particulate solution means stop using it.
| Form | Temperature | Note |
|---|---|---|
| Capsules (sealed container) | Room temperature | Keep in a cool, dry, dark place. Stable up to 12 months at room temperature. |
| Lyophilized vial (long-term) | -4 °F (-20 °C) or colder | Best for long storage. Stable up to 24 months. |
| Lyophilized vial (short-term) | 35.6 to 46.4 °F (2 to 8 °C) | Acceptable for short transit and short holds. |
| Reconstituted vial | 35.6 to 46.4 °F (2 to 8 °C) | Refrigerate. Use within 2 to 4 weeks. Do not refreeze. |
| Appearance | Clear after mixing | Cloudy or particulate solution means stop using it. |
Capsules at room temperature is fine. Reconstituted vials should never be left out for more than a few hours.
5-Amino-1MQ Protocol Mistakes & Troubleshooting
I can't sleep after starting
Move all dosing to the morning. Evening or even midday dosing is the most common cause of insomnia with this compound.
I missed a daily dose
Skip the missed dose and resume the next day in the morning. Do not double up.
I am not seeing fat loss at week 4
Expected. Most reports describe first changes at weeks 4 to 6, with peak effect at 8 to 12 weeks. The mechanism is slow.
The vial looks cloudy after mixing
Stop using it. Cloudy solution can mean degradation or contamination. Reconstituted 5-Amino-1MQ should be clear.
I tried injecting 100 mg and it took 8 mL
Correct — this is exactly why the oral route is preferred for higher doses. Switch to capsules at higher doses, or split the subQ dose across multiple sites if you must inject.
My resting heart rate went up 5 bpm
Reported as a mild stimulant-like effect in the first 1 to 2 weeks. If it climbs higher, stays elevated past 2 weeks, or causes symptoms, stop and consult a clinician.
5-Amino-1MQ Regulatory Status
As of May 2026, 5-Amino-1MQ is not FDA-approved for any human use. It has no approved drug label, no compounding pharmacy availability, and no recognized dietary supplement status under DSHEA.
Products sold as 5-Amino-1MQ capsules or vials are marketed under research-use-only labeling. They are not regulated as drugs and are not regulated as supplements. Quality, identity, and purity depend entirely on the supplier.
Pharmaceutical pipeline: there are no Phase 1 through Phase 3 trials of 5-Amino-1MQ itself registered on ClinicalTrials.gov as of May 2026. Related NNMT-inhibitor programs are at the preclinical or early discovery stage in industry.
Status checked May 2026
Regulatory status can change. Confirm current FDA approval and trial status on FDA.gov and ClinicalTrials.gov before relying on this paragraph for planning.
5-Amino-1MQ vs AOD-9604 vs Semaglutide vs NAD+
5-Amino-1MQ is often compared to fat-loss peptides and to NAD+ boosters. The four below sit closest to it in research community use.
Fat-loss and metabolic compound comparison
Compound
5-Amino-1MQ
Mechanism
NNMT inhibitor; raises NAD+, shrinks fat cells
Route
Oral capsule (50–150 mg/day)
Acts on appetite?
No
FDA status
Not FDA-approved
Compound
AOD-9604
Mechanism
Modified GH fragment; promotes fat oxidation
Route
Subcutaneous injection
Acts on appetite?
No
FDA status
Not FDA-approved
Compound
Semaglutide
Mechanism
GLP-1 receptor agonist; suppresses appetite
Route
Subcutaneous injection or oral
Acts on appetite?
Yes (strong)
FDA status
FDA-approved (T2D and obesity)
Compound
NAD+ (intravenous or subcutaneous)
Mechanism
Direct NAD+ supplementation
Route
IV infusion or subcutaneous
Acts on appetite?
No
FDA status
Not FDA-approved as a drug
| Compound | Mechanism | Route | Acts on appetite? | FDA status |
|---|---|---|---|---|
| 5-Amino-1MQ | NNMT inhibitor; raises NAD+, shrinks fat cells | Oral capsule (50–150 mg/day) | No | Not FDA-approved |
| AOD-9604 | Modified GH fragment; promotes fat oxidation | Subcutaneous injection | No | Not FDA-approved |
| Semaglutide | GLP-1 receptor agonist; suppresses appetite | Subcutaneous injection or oral | Yes (strong) | FDA-approved (T2D and obesity) |
| NAD+ (intravenous or subcutaneous) | Direct NAD+ supplementation | IV infusion or subcutaneous | No | Not FDA-approved as a drug |
These compounds are not interchangeable. Each has its own evidence base and safety boundary.
Plain-English summary: 5-Amino-1MQ and AOD-9604 both target fat without touching appetite. Semaglutide works on appetite but does not directly raise NAD+. NAD+ supplementation adds NAD+ from the outside; 5-Amino-1MQ helps the body make and keep more NAD+ from the inside. Some research community protocols stack 5-Amino-1MQ with AOD-9604 or with a GLP-1 drug, but no human study has tested those combinations.
FAQ
Q1: What is 5-Amino-1MQ?
5-Amino-1MQ is short for 5-amino-1-methylquinolinium. It is a small synthetic molecule that blocks an enzyme called NNMT (nicotinamide N-methyltransferase). Researchers study it for fat-cell shrinkage, higher NAD+ levels, and metabolic support — without affecting appetite.
Q2: Is 5-Amino-1MQ a peptide?
No. 5-Amino-1MQ is a small molecule, not a chain of amino acids. It is often sold alongside research peptides because it fits the same metabolic research space, but chemically it is closer to a small-molecule drug than to peptides like BPC-157 or semaglutide.
Q3: Is 5-Amino-1MQ FDA-approved?
No. As of May 2026, 5-Amino-1MQ has no FDA-approved use. It is sold under research-use-only labeling and is not regulated as a dietary supplement either. No human clinical trials have been published.
Q4: How much 5-Amino-1MQ do people take?
Research community use most often centers on 100 mg per day oral, taken in the morning. The full range reported is 50 to 150 mg per day, usually starting at 50 mg for the first 1 to 2 weeks and increasing if well tolerated. These numbers come from rodent studies scaled to a human size, not from human clinical trials.
Q5: What is the injection dose for 5-Amino-1MQ?
Subcutaneous use is uncommon and dose-limited. A 50 mg vial mixed with 3.0 mL of bacteriostatic water gives about 16.7 mg/mL, and the example subcutaneous range is 2.5 to 5 mg per day. Anything higher than that quickly becomes too much volume for one subQ site, which is why oral capsules are the standard route.
Q6: Oral capsule or subcutaneous injection — which is better?
Oral is the standard. 5-Amino-1MQ has good oral absorption based on cell-uptake testing (Neelakantan 2018), and the typical 50 to 150 mg dose is far too large to inject comfortably. The subcutaneous route exists for researchers using a lyophilized vial format, but it is limited to small doses.
Q7: What are the main side effects?
The most common reports are mild stimulant-like effects (warmth, slightly higher resting heart rate), insomnia if dosed late in the day, and mild stomach upset with capsules. Injection-site stinging happens with the subQ route. Long-term human safety data does not exist.
Q8: Who should avoid 5-Amino-1MQ?
Pregnant or breastfeeding people, anyone with active cancer or a recent cancer history, anyone with liver disease, children and teenagers, and anyone with known sleep disorders should avoid 5-Amino-1MQ outside formal research supervision.
Q9: How long does it take to work?
Research community reports describe first measurable body composition changes at weeks 4 to 6, with peak effect at weeks 8 to 12. The mechanism is slow because it works by reprogramming fat cells, not by suppressing appetite.
Q10: How long should a 5-Amino-1MQ cycle be?
Common research community cycles run 8 to 12 weeks on, followed by 4 to 6 weeks off. The off-period gives baseline NNMT activity a chance to reset before the next cycle.
Q11: Can 5-Amino-1MQ be stacked with semaglutide or AOD-9604?
Some research community protocols combine 5-Amino-1MQ with AOD-9604 (fat oxidation) or with a GLP-1 drug like semaglutide (appetite suppression), since the mechanisms do not overlap. No human study has tested these combinations.
Q12: Is this page medical advice?
No. This page is an educational research-context reference. 5-Amino-1MQ is not FDA-approved and is not a supplement. Talk to a qualified clinician before considering any use.
Sources & Research
- 1. Neelakantan H, Vance V, Wetzel MD, et al. Selective and membrane-permeable small molecule inhibitors of nicotinamide N-methyltransferase reverse high fat diet-induced obesity in mice. Biochemical Pharmacology (2018)
- 2. Babula JJ, Bui D, Stevenson HL, Watowich SJ, Neelakantan H. Nicotinamide N-methyltransferase inhibition mitigates obesity-related metabolic dysfunction. PubMed (peer-reviewed) (2024)
- 3. Kraus D, Yang Q, Kong D, et al. Nicotinamide N-methyltransferase knockdown protects against diet-induced obesity. Nature (2014)
- 4. Sampson CM, Dimet AL, Neelakantan H, et al. Combined nicotinamide N-methyltransferase inhibition and lean-diet substitution reduces body weight and liver fat in obese mice. Scientific Reports (2021)
- 5. Neelakantan H, Brightwell CR, Graber TG, et al. Small molecule nicotinamide N-methyltransferase inhibitor activates muscle stem cells and progenitor cell function. Biochemical Pharmacology (2019)
- 6. Pissios P. Nicotinamide N-Methyltransferase: More Than a Vitamin B3 Clearance Enzyme. Trends in Endocrinology and Metabolism (2017)
- 7. National Center for Biotechnology Information. PubChem Compound Summary for 5-Amino-1-methylquinolinium (5-Amino-1MQ). PubChem (2026)
- 8. U.S. Food and Drug Administration. Drugs@FDA: search confirms no approved 5-Amino-1MQ product as of May 2026. FDA.gov (2026)
- 9. ClinicalTrials.gov. Search results for 5-Amino-1MQ and NNMT inhibitor (no active human trials registered as of May 2026). ClinicalTrials.gov (2026)
Related Dosing Protocols
Educational use only
This guide is an educational research reference, not medical advice or a treatment plan. 5-Amino-1MQ is not FDA-approved for human use.
Calculate vial math
Use the calculator for custom vial size, BAC-water volume, and syringe-unit math.
Open Calculator
Written by Garret Grant
Founder & Lead Researcher · B.S. Civil Engineering, UCLA
Last updated: May 2026
Human-researched and AI-assisted with full editorial review. I verify sources, protocol interpretation, and final judgments personally. See methodology.
Share this page